Extension of Time to File SOU

OSPREY THERAPEUTICS

Ionis Pharmaceuticals, Inc.

Request for Extension of Time to File a Statement of Use

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005)
OMB No. 0651-0054 (Exp 12/31/2020)

Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))


The table below presents the data as entered.

Input Field
Entered
SERIAL NUMBER 87725257
LAW OFFICE ASSIGNED LAW OFFICE 115
MARK SECTION
MARK OSPREY THERAPEUTICS (see, http://uspto.report/TM/87725257/mark.png)
STANDARD CHARACTERS YES
USPTO-GENERATED IMAGE YES
LITERAL ELEMENT OSPREY THERAPEUTICS
OWNER SECTION (current)
NAME Ionis Pharmaceuticals, Inc.
MAILING ADDRESS 2855 Gazelle Court
CITY Carlsbad
STATE California
ZIP/POSTAL CODE 92010
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
OWNER SECTION (proposed)
NAME Ionis Pharmaceuticals, Inc.
MAILING ADDRESS 2855 Gazelle Court
CITY Carlsbad
STATE California
ZIP/POSTAL CODE 92010
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
EMAIL XXXX
CORRESPONDENCE INFORMATION (current)
NAME Anne H. Peck
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE trademarks@cooley.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) apeck@cooley.com; dkoons@cooley.com
CORRESPONDENCE INFORMATION (proposed)
NAME Anne H. Peck
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE trademarks@cooley.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) apeck@cooley.com; dkoons@cooley.com; bfocarino@cooley.com
DOCKET/REFERENCE NUMBER 097721-20084
GOODS AND/OR SERVICES SECTION
INTERNATIONAL CLASS 005
CURRENT IDENTIFICATION Pharmaceutical preparations and human therapeutic preparations for treating and preventing amyloidosis, genetic diseases, disorders and conditions, and protein diseases, disorders and conditions; pharmaceutical preparations and human therapeutic preparations for treating neuropathy, neurological dysfunction, and damage to nerves, tissue, organs, intestinal tract, or bone marrow; injectable drugs for reducing production of transthyretin; antisense drugs
GOODS OR SERVICES KEEP ALL LISTED
EXTENSION SECTION
EXTENSION NUMBER 4
ONGOING EFFORT product or service research or development
ALLOWANCE MAIL DATE 07/10/2018
STATEMENT OF USE NO
PAYMENT SECTION
NUMBER OF CLASSES 1
SUBTOTAL AMOUNT [EXTENSION FEE] 125
TOTAL AMOUNT 125
SIGNATURE SECTION
SIGNATURE /Clifford E Ford/
SIGNATORY'S NAME Ford, Clifford E.
SIGNATORY'S POSITION Vice President, Patents and Senior Patent Counsel
DATE SIGNED 06/30/2020
SIGNATORY'S PHONE NUMBER 650-843-5000
FILING INFORMATION
SUBMIT DATE Tue Jun 30 19:17:47 ET 2020
TEAS STAMP USPTO/ESU-XX.XXX.XXX.XXX-
20200630191747155940-8772
5257-7104de7a3521dfb5ab87
74ef9dc7cc2d07065cb75edd3
4c4c23c04c9d5940-DA-17467
314-20200630161650502458



Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005)
OMB No. 0651-0054 (Exp 12/31/2020)


SOU Extension Request
(15 U.S.C. Section 1051(d))


To the Commissioner for Trademarks:

MARK: OSPREY THERAPEUTICS (see, http://uspto.report/TM/87725257/mark.png)
SERIAL NUMBER: 87725257

OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: Ionis Pharmaceuticals, Inc., having an address of
      2855 Gazelle Court
      Carlsbad, California 92010
      United States
Proposed: Ionis Pharmaceuticals, Inc., having an address of
      2855 Gazelle Court
      Carlsbad, California 92010
      United States
      Phone:
      Fax:
      Email: XXXX

The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application.    The Notice of Allowance mailing date was 07/10/2018.

For International Class 005:
Current identification: Pharmaceutical preparations and human therapeutic preparations for treating and preventing amyloidosis, genetic diseases, disorders and conditions, and protein diseases, disorders and conditions; pharmaceutical preparations and human therapeutic preparations for treating neuropathy, neurological dysfunction, and damage to nerves, tissue, organs, intestinal tract, or bone marrow; injectable drugs for reducing production of transthyretin; antisense drugs

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class.


This is the fourth extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with each of those goods/services covered by the extension request: product or service research or development

Correspondence Information (current):
      Anne H. Peck
      PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@cooley.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): apeck@cooley.com; dkoons@cooley.com

Correspondence Information (proposed):
      Anne H. Peck
      PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@cooley.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): apeck@cooley.com; dkoons@cooley.com; bfocarino@cooley.com


Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).





A fee payment in the amount of $125 will be submitted with the form, representing payment for 1 class.


Declaration

STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section 1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.

DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made on information and belief are believed to be true.


Signature: /Clifford E Ford/      Date Signed: 06/30/2020
Signatory's Name: Ford, Clifford E.
Signatory's Position: Vice President, Patents and Senior Patent Counsel
Signatory's Phone: 650-843-5000

RAM Sale Number: 87725257
RAM Accounting Date: 06/30/2020

Serial Number: 87725257
Internet Transmission Date: Tue Jun 30 19:17:47 ET 2020
TEAS Stamp: USPTO/ESU-XX.XXX.XXX.XXX-202006301917471
55940-87725257-7104de7a3521dfb5ab8774ef9
dc7cc2d07065cb75edd34c4c23c04c9d5940-DA-
17467314-20200630161650502458




uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed